HCA Healthcare: Strong Operations, Heavy Debt, and an Over-demanding Price

The Quarter in Context

HCA Healthcare reported revenue of $19.849 billion for the quarter from July 1 through September 30, 2026, up 3.6% from $19.161 billion in the comparable 2025 quarter. Net income attributable to HCA was $1.579 billion, versus $1.643 billion, while diluted earnings per share increased from $6.96 to $7.27 because diluted weighted-average shares fell from 236.181 million to 217.212 million.

The quarter contained both operating improvement and earnings pressure. Revenues exceeded $19.849 billion, but salaries and benefits rose to $8.581 billion, supplies to $2.822 billion, and other operating expenses to $4.548 billion. Income before taxes consequently fell from $2.418 billion to $2.370 billion. The quarter included a $13 million gain on sales of facilities; that gain is not operating evidence of recurring profit growth.

Cash generation remained substantial, but the comparison requires period discipline. Author subtraction of nine-month operating cash flow of $8.810 billion for January 1 through September 30, 2026 less $4.349 billion for January 1 through June 30, 2026 produces derived Q3 operating cash flow of $4.461 billion. The same method produces derived Q3 capital expenditure of $1.357 billion and a derived Q3 accounting free-cash-flow proxy of $3.104 billion. These are author calculations from cumulative SEC statements, not directly reported standalone-quarter cash-flow lines.

The broader context is stronger than the quarter’s net-income comparison alone. Trailing-twelve-month revenue through September 30, 2026 was $78.701 billion, net income attributable to HCA was $6.776 billion, and the trailing-twelve-month accounting free-cash-flow proxy was $5.973 billion. The cash measure is operating cash flow less property-and-equipment purchases; it is not normalized owner earnings, and the filings do not separate maintenance from growth capital expenditure.

Business Model and Profit Engine

HCA is a downstream healthcare service provider. Patients receive acute-care, surgical, diagnostic, emergency, outpatient and related services, but patients are usually not the ultimate payer. Medicare, Medicaid, managed-care plans and commercial insurers pay on prescribed or negotiated terms; patients may owe deductibles, copayments and uninsured balances. For the quarter ended September 30, 2026, managed care and insurers available $9.574 billion, or 48.3% of revenue, while Medicare and managed Medicare available $6.455 billion, or 32.5% combined.

Revenue is therefore transactional in the accounting sense—each patient encounter creates a service obligation—but economically recurring because medical needs recur and HCA operates a large installed network. At September 30, 2026, affiliates owned and operated 189 hospitals, 117 freestanding surgery centers and 30 freestanding endoscopy centers in 19 states and England, alongside outpatient and ancillary services. Inpatient performance obligations are generally satisfied over about five days, while outpatient obligations are generally satisfied in less than one day.

HCA reports one line of business, with National, Atlantic and American geographic groups plus Corporate and other. For 2025, group revenue was $21.278 billion, $24.709 billion and $26.445 billion respectively, while adjusted segment EBITDA was $5.103 billion, $5.642 billion and $6.296 billion. Those segment disclosures are non-GAAP analytical measures, and current-quarter segment revenue and margins were not available. Cross-subsidy and product-level contribution therefore cannot be established for Q3.

The profit bridge begins with revenue less patient-care costs: salaries and benefits, supplies, other operating expenses, equity earnings and depreciation. Corporate costs were $146 million in Q3 2026, after which interest, taxes and noncontrolling interests determine earnings attributable to HCA. Labor and facilities are partly fixed over short periods, so volume or revenue-per-admission changes can create operating leverage; conversely, wage inflation or underused capacity can move margins quickly.

Capital intensity is substantial. Property and equipment was $69.632 billion at cost and $32.268 billion net at September 30, 2026. Accounts receivable was $11.509 billion and days revenues in accounts receivable was 53 days in Q3 2026, compared with 50 days a year earlier. HCA does not disclose a maintenance-versus-growth split, so investors cannot treat all capex as either essential maintenance or discretionary growth. Customer concentration is not quantified; payer concentration is visible, and shifts in government reimbursement, exchange enrollment and commercial contract terms directly affect collections and pricing.

Earnings Quality and Cash Conversion

Quarterly cash-flow calculations below subtract two reported cumulative statements. These are author calculations, not directly reported quarterly line items. Amounts are USD.

Where the issuer reports cash flow and capital expenditure cumulatively, the standalone-quarter cash-flow figures are derived by subtracting the preceding cumulative filing. They are calculations from SEC facts rather than separately reported quarterly line items.

Cash conversion was strong in absolute terms but weaker on a year-over-year comparison. Derived Q3 operating cash flow of $4.461 billion compared with derived $4.416 billion in the quarter ended September 30, 2025. Derived capital expenditure increased from $1.288 billion to $1.357 billion, leaving a derived accounting free-cash-flow proxy of $3.104 billion versus $3.328 billion.

The nine-month statements explain why the quarter should not be treated as the full earnings story. Operating cash flow fell from $10.277 billion for January 1 through September 30, 2025 to $8.810 billion for January 1 through September 30, 2026. HCA attributed the $1.467 billion decline primarily to $472 million of unfavorable working-capital changes and a $1.190 billion increase in income-tax payments related to a 2025 deferral for Tennessee taxpayers, partly offset by higher adjusted net income.

Several income and cash items require normalization care. The nine-month 2026 effective tax provision included a $110 million employee-equity-settlement tax benefit, versus $45 million in the prior-year nine months. The filing also disclosed $22 million of facility-sale gains for the nine months and $13 million for the standalone quarter; those gains cannot explain the quarterly earnings trend and are not a recurring operating engine.

For the quarter, total expenses before interest, equity earnings and depreciation increased faster than revenue. Other operating expenses rose $387 million year over year. Across the nine months, salaries and benefits fell to 42.5% of revenue from 43.7%, and supplies fell to 14.5% from 15.0%, but other operating expenses rose to 23.3% from 21.0%, partly because of Medicaid directed and supplemental payment program expenses and professional fees. This is mixed evidence: some labor and supply efficiencies were offset by higher expenses elsewhere.

The balance sheet is the principal earnings-quality constraint. At September 30, 2026, cash was $908 million, current debt including short-term borrowings was $8.093 billion, and noncurrent long-term debt was $42.400 billion, producing calculated total debt of $50.493 billion and net debt of $49.585 billion. The filing’s $44.766 billion long-term-debt aggregate includes current maturities and is not added again.

Business Quality, Moat, and Industry Position

On the available evidence, the company is best described as an important participant, not a demonstrated core supply-chain bottleneck. This classification describes strategic position only; it is not independent proof of a moat or valuation upside.

HCA’s strongest observable advantage is scale in a fragmented, operationally demanding service network. The company can spread clinical, administrative, purchasing, legal, human-resources and information-technology capabilities across hospitals and outpatient sites. Local hospital networks, physician relationships, licensed capacity and an installed base of 189 hospitals make a direct physical substitute less immediate than the bed count alone suggests. However, these are supporting facts rather than proof of durable pricing power.

Demand is broadly non-discretionary, yet revenue is not immune to economic or policy shocks. Patient volume, service mix, payer coverage, reimbursement rates and contractual renewals all matter. For Q3 2026, managed-care and insurer revenue was hurt by the expiration of enhanced premium tax credits and related administrative reforms. Medicaid revenue for the nine months benefited from state directed and supplemental payment approvals, particularly a Florida program, making part of the recent revenue increase policy-dependent rather than a clean test of organic pricing power.

The supply-chain position is that of an important downstream service participant, not a core bottleneck. HCA depends on clinical labor, physicians, pharmaceuticals, medical supplies, utilities and construction capacity, but its value capture comes from coordinating care and facility capacity rather than controlling scarce upstream inputs. Substitution varies by service: emergency and acute care are locally constrained, while elective procedures and some outpatient services face greater provider choice. Licensure, workforce, physician alignment and payer-contract barriers support continuity, but do not eliminate reimbursement or volume risk.

The observable durability test is therefore operational rather than narrative: volumes, revenue per equivalent admission, labor efficiency, payer mix and margins must persist through policy changes. The Fisher-style ceiling is only partly met. HCA has a long runway in expanding outpatient networks and improving local density, and nine-month same-facility revenue rose 5.8%, supported by 3.4% revenue-per-equivalent-admission growth and 2.3% equivalent-admission growth. But externally verifiable customer satisfaction, referral retention, physician retention and unit-level returns on individual investments are not available, so the ceiling cannot be scored confidently.

Management and Capital Allocation

Observable conduct suggests a strong preference for debt-funded expansion and large share repurchases. During January 1 through September 30, 2026, HCA paid $6.605 billion to repurchase common stock and $519 million for dividends. It also paid $942 million to acquire nonhospital healthcare entities, spent $3.707 billion on property and equipment, and increased total indebtedness. Shares outstanding fell from 224.605 million at December 31, 2025 to 210.881 million at September 30, 2026, and the quarter included 7.229 million shares repurchased at an average $410.85.

That allocation has a coherent per-share logic: HCA is buying back stock while investing in capacity and entering adjacent assets. Yet the sequence also deserves scrutiny. HCA funded significant repurchases and expansion alongside a net debt position of $49.585 billion, while operating cash flow declined over the first nine months. The benefit of repurchasing below intrinsic value can outweigh the cost, but buying at an excessive price destroys value even as the share count falls. The observable prices therefore require comparison with value, not simply with current earnings.

The company maintains access to debt markets and disclosed $2.226 billion available under its senior unsecured credit facility at September 30, 2026 after letters of credit and its commercial-paper-linked availability condition. It expects to finance capital expenditures with internally generated and borrowed funds. Management also disclosed a 2026 capital-expenditure expectation of $5.0 billion to $5.5 billion, excluding acquisitions, and $8.6 billion of estimated additional costs over five years for projects under construction. These are management expectations, not realized spending or company forecasts of shareholder returns.

Culture is partly observable through operating discipline, capital intensity, disclosure and shareholder returns, but not fully measurable. The filing provides detailed payer, facility, segment and risk information, and management disclosed that internal controls were effective. Unknowns remain around management compensation incentives, acquisition hurdle rates and local management depth. A large repurchase program creates an incentive to demonstrate near-term per-share progress; it does not itself prove durable capital allocation.

Valuation and What the Market Already Expects

At the November 11, 2026 market close, HCA’s share price was $504.42 and market capitalization was $105.370 billion. Against the $5.973 billion trailing-twelve-month accounting free-cash-flow proxy through September 30, 2026, the equity produces a low cash-flow yield. Because market capitalization already represents equity value, adding cash and subtracting debt is unnecessary for this market-capitalization comparison; the enterprise-value bridge is used to value cash flows before adding the same-date $49.585 billion net-debt adjustment.

The burden is not merely a low cash yield. HCA has $50.493 billion of total debt, $1.790 billion of nine-month interest expense, negative stockholders’ equity of $8.077 billion and ongoing capital requirements. A reverse cash-flow sensitivity implies that the dated market price requires materially faster long-term free-cash-flow growth than the observed revenue trend. That is a market expectation, not a company forecast and not proof that such growth is impossible.

The dated price therefore lacks a Graham-style margin of safety unless an investor can independently demonstrate that HCA will combine high-single-digit or better cash-flow growth with durable margins, limited dilution and disciplined debt service. A falling share price or successful repurchases would not establish that protection. The price reflects substantial operating execution already.

Ten-Year Cash Flow to Fair Market Value

The starting free cash flow is reported operating cash flow less reported total capital expenditure: an accounting cash-flow proxy, not normalized sustainable earnings or maintenance-capex owner earnings. Every growth rate, discount rate and terminal rate below is an explicit editorial assumption rather than company guidance. Each annual cash flow is forecast and discounted separately; terminal value is year-ten free cash flow multiplied by one plus terminal growth, divided by discount rate minus terminal growth, and then discounted back ten years. Fair market capitalization equals that explicit ten-year present value plus discounted terminal value and the supplied same-date balance-sheet adjustment. The supplied current cash and debt inputs reconcile to the dated adjustment shown below. Missing inputs are never treated as zero; an unavailable bridge would block this calculation. The share count is derived from the dated market capitalization and share price so US shares and foreign ADRs use a consistent traded-security denominator.

In the reverse-DCF, holding the 9% discount rate and 3% terminal growth fixed, and solving only for one constant growth rate rather than using the base-case growth path, the current market capitalization implies roughly 8.4% annual free cash flow growth for ten years. This is a sensitivity framework, not a price target: the terminal-value share shows how strongly each result depends on assumptions beyond the explicit forecast. For positive scenario equity values, negative margin of safety means the current market capitalization exceeds the scenario value. For zero or negative scenario equity values, a margin-of-safety percentage is not meaningful; the obligations exhaust the modeled enterprise value.

Five Value-Investing Lenses

Benjamin Graham Lens

The Graham question is whether the investment survives disappointment without destroying principal and whether the market price compensates for that risk. HCA has a substantial cash engine, but the downside floor is weak: cash was $908 million against $50.493 billion of total debt, stockholders’ equity was negative $8.077 billion, and refinancing matters. A famous hospital franchise and a high share price are not evidence of cheapness. The dated price lacks a margin of safety, so this is not Graham-style value; it is a quality-at-price speculation unless future cash generation proves much stronger.

Benjamin Franklin Lens

Franklin’s modern application is thrift, discipline, compounding and opportunity cost. HCA’s repurchases materially reduced the share count, and operating cash flow can compound value when reinvested at attractive returns. However, repurchases, dividends, acquisitions and $3.707 billion of nine-month capex were funded in a highly leveraged structure, while nine-month operating cash flow declined. Buying shares only creates value below intrinsic value; using borrowed funds to buy an over-demanding price converts an attractive business into a poor investment.

Warren Buffett Lens

HCA’s owner-earnings starting point is its $5.973 billion trailing accounting free-cash-flow proxy, not a claimed Buffett-defined owner-earnings measure. It includes no normalization for maintenance versus growth capex, working-capital normalization, stock compensation or noncontrolling interests, so the bridge requires caution. Consolidated cash flow also is not automatically attributable entirely to common shareholders: nine-month net income attributable to noncontrolling interests was $738 million. The moat appears operational, but leverage and capital allocation determine how much value reaches each share.

Charlie Munger Lens

Munger’s lens asks where incentives can distort judgment. The $6.605 billion nine-month repurchase program rewards a smaller share count and per-share metrics, while the $10 billion authorization creates a large opportunity to overpay. Meanwhile, debt expansion makes refinancing conditions part of operating quality. The most likely wrong assumption is that past operating execution and repurchase accretion will continue even if reimbursement pressure, uncompensated care or capex intensity worsens. Reverse the thesis: lower margins or persistent cash-tax leakage would undermine the valuation burden.

Li Lu Lens

HCA sits inside a comprehensible circle of competence: healthcare services, local hospital operations, payer reimbursement, labor and capital allocation. Its culture appears operationally focused, but culture cannot be fully proven from financial statements. Durability depends on physician alignment, service quality, local market density, efficient facilities and disciplined expansion—not simply the number of hospitals. Permanent-loss control is constrained by leverage and policy risk. Without available customer, physician and supplier evidence, confidence in the moat and in a culturally durable culture must remain moderate.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

The first observable thesis breaker is cash-flow deterioration: operating cash flow falling materially below the $8.810 billion nine-month 2026 level without a clearly temporary tax-timing cause, or accounting free cash flow failing to cover capital expenditure, interest and distributions to noncontrolling interests. The second is margin pressure: salaries and benefits rising faster than revenue, other operating expenses remaining elevated, or volume and revenue-per-admission growth turning negative. The third is balance-sheet stress: refinancing at materially worse terms, inability to maintain liquidity, or debt-funded repurchases that outpace sustainable cash generation.

The fourth is policy and payer erosion: Medicaid directed-payment benefits reversing, exchange enrollment shrinking further, commercial contracts repricing downward, or uncompensated care increasing materially. The fifth is capital-allocation failure: acquisitions or repurchases producing weak returns, share issuance offsetting the reduction in share count, or construction commitments outrunning operating cash generation. Any of these would weaken the assumption that the market’s required operating progress is achievable.

The most plausible permanent-loss path combines lower reimbursement, persistent labor inflation and heavy debt. That combination can reduce cash available for facilities and creditors, increase refinancing risk and leave common shareholders exposed to dilution or value impairment. The opportunity cost is also material: accepting a richly valued levered company may prove inferior to owning a less exciting business at a much lower price.

Investment Conclusion

HCA is a capable, strategically important healthcare operator with recurring patient demand, scale and strong absolute cash generation. Yet the September 30, 2026 balance sheet offers little balance-sheet margin of safety, while operating cash flow weakened year over year and policy-dependent revenue items complicate earnings quality. At the November 11, 2026 price, the market already requires substantial operating progress; the valuation burden exceeds what the filing evidence can comfortably support.

The conclusion is Overvalued, not that HCA is a poor business. A materially lower price, sustained cash conversion, durable volume and margin performance, and clearer evidence that debt-funded repurchases create per-share value would be needed to move the conclusion toward “Worth watching.” This article is for educational purposes only and is not investment advice.